MedTrace Logo

Perfusion CT as a Predictor for Response to Antiangiogenic Therapy in Patients With Metastasized Renal Cell Carcinoma

NCT02086734 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 60

Last updated 2018-10-02

No results posted yet for this study

Summary

The purpose of this study is the evaluation of dynamic contrast-enhanced CT (Perfusion-CT) for therapeutic response predicition in patients with metastasized renal carcinoma (mRCC) undergoing antiangiogenetic therapy (AAT) with multikinase inhibitors.

In this study patients with mRCC under AAT will be examined with 3 serial Perfusion - CT scans - partially intergrated in their regular staging CT scheme - at baseline (before AAT start), 1 week after AAT as well as 8 weeks after AAT initialization. Thereby selected intrabdomial or intrathoracic metastases will be monitored longitudinally with perfusion CT. Pretreament and post-treament perfusion characteristics of the assessed metastatic lesions will be quantified and correlated with patient outcome.

Conditions

  • Metastatic Renal Cancer

Interventions

OTHER

Perfusion-CT

1. Baseline Perfusion CT-Scan (before AAT) 2. Follow-Up I Perfusion-CT Scan 7 days after start with AAT 3. Follow-Up II Perfusion-CT Scan 8 weeks after start with AAT

Sponsors & Collaborators

  • Ludwig-Maximilians - University of Munich

    lead OTHER

Principal Investigators

  • Michael Staehler, Prof. Dr. med. · Urologische Klinik und Poliklinik der Universität München

  • Anno Graser, Prof. Dr. med. · Institut für Klinische Radiologie des Klinikums der Universität München

  • Alexander Sterzik, Dr. med. · Institut für Klinische Radiologie des Klinikums der Universität München

  • Jozefina Casuscelli, Dr. med. · Urologische Klinik und Poliklinik der Universität München

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-04-30
Primary Completion
2018-07-31
Completion
2018-07-31

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02086734 on ClinicalTrials.gov